

In the claims:

Claims 1 and 2 (Cancelled)

3. (Currently amended) ~~The polypeptide of claim 2~~ A polypeptide the inhibits complement C1s, wherein the polypeptide is characterized by the formula: “P-N-E-E-[YX<sub>1</sub>X<sub>2</sub>X<sub>3</sub>]-E-[YX<sub>1</sub>X<sub>2</sub>X<sub>3</sub>]-E-[YX<sub>1</sub>X<sub>2</sub>X<sub>3</sub>]-E” (SEQ ID NO:130).

4. (Original) The polypeptide of claim 3, wherein the polypeptide consists of the amino acid sequence: “PNEEY EYEYE” (SEQ ID NO:125).

5. (Cancelled)

6. (Original) A peptide or polypeptide that inhibits complement C1s, wherein the peptide or polypeptide comprises the amino acid sequence “CRLGC” (amino acid residues 64 to 68 of SEQ ID NO:1), wherein the peptide or polypeptide consists of five to thirty amino acid residues.

7. (Original) The peptide or polypeptide of claim 6, wherein the polypeptide consists of the amino acid sequence: “GCDGFKCRLG CTYGFKTDKK GCEAFCTCNT” (SEQ ID NO:53).

8. (Previously presented) The peptide of claim 6, wherein the peptide consists of the amino acid sequence: “CRLGC” (amino acid residues 64 to 68 of SEQ ID NO:1).

18. (Currently amended) A composition, comprising a carrier, and a peptide or a polypeptide of any one of claims ~~1, 5, 3~~ or 6.